Welcome to our dedicated page for Mirum Pharmaceuticals news (Ticker: MIRM), a resource for investors and traders seeking the latest updates and insights on Mirum Pharmaceuticals stock.
Mirum Pharmaceuticals (MIRM) delivers innovative therapies for rare liver diseases through targeted IBAT inhibitor development. This page provides centralized access to official announcements, clinical trial updates, and strategic developments from the biopharmaceutical innovator.
Investors and healthcare professionals will find timely updates on regulatory milestones, partnership agreements, and pipeline advancements. Our curated feed includes verified press releases about Maralixibat approvals, Volixibat trial progress, and corporate initiatives addressing conditions like progressive familial intrahepatic cholestasis.
Key updates cover FDA communications, research collaborations, and commercialization strategies for orphan drug therapies. All content is sourced directly from Mirum’s disclosures to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to Mirum’s latest advancements in minimally absorbed liver disease treatments. Check regularly for critical updates impacting clinical development timelines and therapeutic availability.
Mirum Pharmaceuticals presented significant findings from clinical studies on maralixibat at the 54th Annual ESPGHAN Meeting. The data showed a 70% reduction in event-free survival and significant improvements in transplant-free survival in patients with Alagille syndrome. Notably, 76% and 79% of patients remained event-free and transplant-free at six years. Maralixibat also demonstrated improved growth in pediatric patients over four years.
Furthermore, the treatment showed a notable impact on health-related quality of life, particularly in patients with BSEP deficiency. This data enhances the understanding of maralixibat's clinical potential.
Mirum Pharmaceuticals (NASDAQ: MIRM) presented significant findings at the 2022 International Liver Congress in London, highlighting the debilitating effects of pruritus on patients with primary sclerosing cholangitis (PSC). A multinational survey with 482 patients revealed that 91% experienced itch, severely impacting their quality of life. Importantly, current treatments provided limited relief. Mirum is evaluating volixibat, an IBAT inhibitor, to address this unmet need. The company is also exploring optimal dosing strategies for its drugs in clinical trials.
Mirum Pharmaceuticals (Nasdaq: MIRM) presents data at the International Liver Congress™ and the 54th Annual ESPGHAN Meeting. Eight abstracts are accepted, including three oral presentations, with notable research on maralixibat for Alagille syndrome. This data includes predictors of event-free survival and is nominated for the prestigious Alex Mowat Prize. Additionally, Mirum will host scientific symposia at both events, enhancing its position in the treatment of rare liver diseases.
On June 10, 2022, Mirum Pharmaceuticals granted inducement awards under its 2020 Inducement Plan to eight new employees. These awards consist of non-qualified stock options for 43,550 shares and 21,800 restricted stock units (RSUs). The stock options have an exercise price of $21.36 and will vest over four years, while RSUs will vest over three years. The awards comply with Nasdaq Listing Rule 5635(c)(4) and are aimed at incentivizing the new hires to drive growth in Mirum's rare disease treatments.
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) announced the appointment of Saira Ramasastry to its board of directors and audit committee. Ramasastry brings over 20 years of financial leadership, including her experience at Merrill Lynch & Company. CEO Chris Peetz emphasized her strategic experience as crucial for expanding the company’s reach and enhancing its rare disease pipeline. Mirum develops therapies like LIVMARLI® for liver diseases and has ongoing clinical trials for innovative treatments, showing commitment to advancing care for patients.
Mirum Pharmaceuticals has acquired Satiogen Pharmaceuticals, consolidating its licensing obligations for LIVMARLI® and volixibat. This strategic move is anticipated to improve cash flow and reduce royalty payments to high single digits. The total transaction value includes 841,792 shares of common stock and approximately
Mirum Pharmaceuticals (NASDAQ: MIRM) has announced its participation in key virtual investor conferences. The H.C. Wainwright Global Investment Conference is set for May 24, 2022, with a fireside chat starting at 8:30 a.m. ET. Following this, Mirum will present at the Jefferies Healthcare Conference on June 9, 2022, from 9:00-9:30 a.m. ET. The company focuses on treatments for rare liver diseases, with its approved drug LIVMARLI for Alagille syndrome and investigational treatments for various liver diseases.
Mirum Pharmaceuticals, Inc. (MIRM) has granted inducement awards to 18 new employees, comprising 178,000 non-qualified stock options and 52,677 restricted stock units (RSUs) as of May 10, 2022. The stock options have an exercise price of $22.55, corresponding to Mirum's closing price on that date, and will vest over four years. The RSUs will vest over three years. These awards are part of Mirum's 2020 Inducement Plan and adhere to Nasdaq Listing Rule 5635(c)(4). Mirum focuses on rare diseases and is advancing its clinical pipeline for liver diseases.
Mirum Pharmaceuticals reported a total revenue of $12.9 million for Q1 2022, with net product revenue from LIVMARLI® at $10.9 million. This marks significant growth compared to the previous year's figures. Operating expenses decreased to $45.6 million from $47.6 million in Q1 2021. Despite a net loss of $36.6 million (or $1.17 per share), it was an improvement from last year’s loss of $50.5 million. The company anticipates key clinical trial data and regulatory approvals in late 2022, enhancing prospects for future revenue growth.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) will report its first quarter financial results on May 5, 2022.
A conference call will be held at 8:30 a.m. ET to discuss the company's progress and priorities for 2022. Investors can join via U.S. toll-free dial-in 844-200-6205 or access the call via webcast. Mirum focuses on rare diseases, with its approved medication LIVMARLI® for cholestatic pruritus in Alagille syndrome. The company is also evaluating investigational treatments for various liver diseases and has submitted a Marketing Authorization Application to the European Medicines Agency.
FAQ
What is the current stock price of Mirum Pharmaceuticals (MIRM)?
What is the market cap of Mirum Pharmaceuticals (MIRM)?
